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Clinical/Scientific Notes
Closure of a patent foramen ovale is
associated with a decrease in prevalence
of migraine
Martijn C. Post, MD; Vincent Thijs, MD; Luc Herroelen, MD; and
Werner I.H.L. Budts, MD, PhD
A patent foramen ovale (PFO) is one of the major causes of right-to-
left shunt, and a causal relationship between migraine and a PFO
has been suggested.1 We evaluated whether percutaneous closure of
a PFO was associated with changes in the prevalence of migraine.
Methods. Patient selection. Patients with a PFO who had a
paradoxical embolic event or systemic desaturation and who un-
derwent a percutaneous closure in our center between February
1999 and September 2002 were included. The medical files were
reviewed. The ethical committee approved the study.
Evaluation of migraine. A questionnaire was composed in
such a way that a neurologist could diagnose migraine with or
without aura (MA and MA) according to the criteria of the
International Headache Society. The questionnaire was sent to all
patients and focused on three periods: 1 year before and 2 months
and at least 6 months after percutaneous closure. Two neurolo-
gists blinded to the patients’ files diagnosed MA and MA.
Statistical analysis. Within-patient comparisons of the absence
or presence of migraine were performed with the McNemar’s paired
2 test. Interobserver reliability was evaluated by measuring the
kappa coefficient. p Value  0.05 was considered significant. All
statistical analyses were performed with GB Stat software (version
8.0; Dynamic Microsystems, Inc., Silver Spring, MD).
Results. Patient characteristics. Seventy-six patients (mean
age, 50.7 12.9 years) were selected, and 66 completed the question-
naire. In 57 patients, the period between PFO closure and complet-
ing the questionnaire was 6 months. The characteristics of patients
who completed the questionnaire are summarized in the table.
Prevalence of migraine. The median time interval between
the occurrence of a paradoxical embolic event and the closing
procedure was 162 days (range, 0 to 3,613 days). The time be-
tween PFO closure and administration of the questionnaire was
579 days (range, 110 to 1,419 days).
Migraine was present in 26 of 66 patients (9 men and 17
women; 39.4%). Twelve (18.2%) had MA, and 14 (21.2%) had
MA. Two months after closure, the prevalence of MA and MA
decreased to 6.1% (4/66) and 6.1% (4/66; p  0.05 vs before clo-
sure). At 6 months or more, the overall prevalence of migraine
was 15.8% (9/57; p  0.05 vs before closure). The prevalences of
MA and MA were 5.3% (3/57; p  0.05 vs before closure) and
10.5% (6/57; p  0.11 vs before closure). The frequency of migraine
attacks also decreased (p  0.05). Seven patients were taking
potential prophylactic migraine drugs 6 months after closure (six,
-blockers; one, calcium antagonists). The kappa coefficient for
interobserver reliability for migraine was 0.8 (p  0.05).
Discussion. Patients with migraine have a high prevalence of
PFO.2 An increased rate of MA among stroke patients with PFO
was found compared with patients with PFO.2 A causal relation-
ship between PFO and migraine has been proposed. In individuals
with a right-to-left shunt, a lower dose of venous trigger sub-
stances may be needed to induce migraine because the shunt
permits the pulmonary filter to be bypassed.1 Moreover, the prev-
alence of migraine seems to decrease subsequent to PFO closure
in patients with decompression illness.3
We evaluated whether PFO closure in patients who mainly
had cryptogenic stroke would be associated with changes in the
prevalence of migraine. We found a high rate of migraine in pa-
tients with PFO (39.4%) and documented a significant and persis-
tent decrease in prevalence of MA 6 months after PFO closure.
The frequency of migraine attacks also decreased significantly.
Our data might fit with the recently reported experience that
MA decreased after PFO closure.4
The prevalence of migraine also decreases with age; how-
ever, we believe that the changes in our study are too pro-
nounced to be explained by the natural history of migraine.5
Most of our patients were treated with low-dose aspirin, which
could also influence migraine prophylaxis. The effect of low-
dose aspirin, if any, seems to be modest.6 The placebo effect in
migraine therapy is potent, but the decrease in prevalence of
migraine in our study seems to be larger than reported placebo
effect rates of 20 to 40%.7
Nevertheless, this study has important limitations. It is a ret-
rospective, nonrandomized trial of patients selected from a
hospital-based database. The questionnaire may be influenced by
recall bias.
The prevalence of migraine in patients with a PFO is high.
After 6 months, percutaneous PFO closure is associated with a
decrease in the prevalence of MA. Whether percutaneous PFO
closure has the potential to manage migraine needs to be deter-
mined in a prospective randomized trial.
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Table Characteristics of patients who completed the
questionnaire
Migraine No migraine p
No. of patients (n) 26 40
Age (y, mean  SD) 55  10 53  12 0.48
Male/female 9/17 27/13 0.05
Indication PFO closure
Stroke (n) 24 37 0.94
Peripheral embolism (n) 2 1 0.33
Brain abscesses (n) 0 1
Desaturation (n) 0 1
Frequency of migraine attacks
prior to closure
Almost monthly (n) 9
Almost weekly (n) 9
Several times a week (n) 8
PFO  patent foramen ovale.
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Prolactinoma presenting as painful
postganglionic Horner syndrome
A.V. Talkad, MD; J.C. Kattah, MD; M.Y. Xu, MD, PhD;
E.H. Orth, DO; and J.Y. Chang, MD
Painful postganglionic Horner syndrome may be the initial pre-
sentation of an internal carotid artery (ICA) dissection and less
frequently is a complication of cluster headache.1 However, it is
not a frequent presentation of pituitary adenoma. We describe a
patient with prolactinoma that initially manifested with painful
Horner syndrome and improved on dopaminergic therapy. Eigh-
teen months after treatment was discontinued, the patient sought
treatment for a cavernous sinus syndrome that responded well to
high-dose dopaminergic therapy.
Case report. A 52-year-old man was examined by one of our
staff neurologists for an intermittent right hemicrania, retro-orbital
pain and a narrowed palpebral fissure in March 1999. He had no
history of alcoholism, head trauma, hypertension, diabetes mellitus,
chronic headaches, impotence, or decreased libido. He smokes one
pack of cigarettes daily. Examination revealed a 2-mm ptosis of
the right upper eyelid and a 2-mm pupil that failed to dilate in
the dark and after hydroxyamphetamine. The left pupil, in
contrast, measured 3 mm and dilated to 5 mm in the dark and
to 8 mm after hydroxyamphetamine. Both pupils reacted to
light and accommodation. Visual acuity (Vac), color vision, vi-
sual fields, funduscopy, and remaining physical examination
were normal. Brain MRI showed a discrete mass surrounding
the carotid artery (figure, left). Serum prolactin level was ele-
vated at 566.4 ng/mL (normal range 0.5 to 18.1 ng/mL). Bro-
mocriptine 5 mg/d was initiated, and the patient experienced
symptomatic improvement during the ensuing 6 months.
Thirty-two months later, he again sought treatment at our
institution for worsening right-sided headache and diplopia. Eigh-
teen months earlier, the patient decided to discontinue his bro-
mocriptine. During the interval, he had no change in his history.
Examination revealed a 4-prism diopter right exophoria and a
partial right oculomotor nerve paresis with partial ptosis of the
upper eyelid; symmetric limitation of infraduction, supraduction,
and adduction; and a 4-mm pupil with preservation of pupillary
responses. Additionally, there was complete right sixth nerve
palsy with hypesthesia in the right V1 and V2 dermatomes. Color
vision, funduscopy, visual fields, and Vac were normal bilaterally.
During the next 2 days, he developed a complete ophthalmoplegia
of the right eye.
Brain MRI showed a 2.2 	 1.8 	 3-cm lesion filling the right
cavernous sinus adjacent to, but not compressing, the optic chiasm
(figure, middle). The tumor now encircled the cavernous portion of
the right ICA. Serum prolactin at that time was 281.3 ng/mL. The
patient was started on bromocriptine 15 mg daily and cabergoline
1 mg twice weekly. Ten days after cabergoline was added, serum
prolactin level decreased to 22.1 ng/mL.
Four months later, follow-up MRI showed a 50% reduction in
tumor bulk with the tumor still encircling the cavernous right ICA
(figure, right). Clinically, he had resolution of the Horner syn-
drome and third and sixth nerve palsies, and return of facial
sensation. In addition, there were no signs of aberrant regenera-
tion. The patient was able to remain compliant with dual dopa-
mine agonist therapy, except for nausea managed with
ondansetron.
Discussion. A pituitary adenoma, presenting as a focal mass
in the cavernous sinus, without diffuse sellar involvement, is dis-
tinctly uncommon. We are unaware of previous reports of pitu-
itary tumors manifesting initially as postganglionic Horner
syndrome. Although our patient did not have symptoms of hyper-
prolactinemia, a markedly increased prolactin level directed us to
this diagnostic possibility. The successful effect of dopaminergic
therapy, with resolution of the presenting symptoms and signs
and virtual normalization of the serum prolactin level, left no
doubt as to the diagnosis.
Prolactinoma is not initially thought of as a cause of an iso-
lated involvement of postganglionic sympathetic fibers. Raeder2
first reported simultaneous impairment of sympathetic and tri-
geminal nerve fibers in a patient with an extrinsic mass lateral to
the cavernous sinus. Our patient mimicked this presentation with
a mass intrinsic to the cavernous sinus. Unlike his case, there was
no involvement of motor trigeminal fibers.
Our patient had already been treated successfully with a
single dopamine agonist but now presented with cavernous si-
nus syndrome after discontinuing therapy for 18 months.3 The
main impetus to try simultaneous, high-dose dopamine agonists
was to elicit a rapid response given the severity of the pain and
ophthalmoplegia and to rule out the possibility of a prolactin-
secreting carcinoma. The remarkable clinical and imaging re-
sponse to dual dopamine agonists essentially served to
elucidate the benign neuroendocrine character of the tumor,
allowing a diagnosis without need for tissue biopsy or malig-
nant tissue markers.4
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Figure. T1-weighted, contrast-enhanced MRI of brain. (Left) April 1999, performed after initial visit. (Middle) August
2002, ~1 month after starting dual agonist therapy. (Right) November 2002, only minimal symptoms present with re-
ported 50% reduction radiographically in tumor bulk.
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IV insulin during acute cerebral infarction in
diabetic patients
Askiel Bruno, MD; Chandan Saha, PhD; Linda S. Williams, MD;
and Ravi Shankar, MD
Although hyperglycemia can be a nonspecific response to stress,
tight glycemic control during acute myocardial infarction1 and in
postoperative ventilated patients2 has been shown to significantly
reduce mortality. Animal3 and human4-6 studies suggest that hy-
perglycemia also augments acute cerebral ischemia, and clinical
efficacy of tight glycemic control during acute cerebral infarction
is being investigated.7 Good glycemic control during acute cerebral
infarction in nondiabetic patients appears feasible and safe, but
this has not been reported in patients with diabetes mellitus.7
Methods. Our Institutional Review Board approved this
study, and all subjects signed a valid informed consent. We pro-
spectively administered an IV insulin protocol initiated within 12
hours after onset of cerebral infarction to 24 consecutive patients
with admission hyperglycemia (9.4 to 22.2 mmol/L or 170 to 400
mg/dL). Nurses supervised closely by the principal investigator
administered the insulin protocol in an open-label fashion.
We modified our insulin protocol after each three to seven
treated subjects to improve glycemic control and minimize hypo-
glycemia while keeping the protocol practical. We adjusted the
insulin infusion rate every 1 to 2 hours if needed based on capil-
lary glucose measurements to maintain the glucose between 3.9
and 7.2 mmol/L (or 70 to 130 mg/dL). Table E-1 shows our initial
and latest insulin protocols (see table E-1 on the Neurology Web
site). Subjects able to eat received diabetic diets, along with sub-
cutaneous insulin 0.12 U/kg before each meal. We continued the
insulin protocol for up to 72 hours (range, 17 to 72 hours; mean,
54 hours). Oral antidiabetic medications were discontinued during
insulin infusion.
We defined hypoglycemia as 3.0 mmol/L (or 54 mg/dL) and
recurrent hyperglycemia as 9.4 mmol/L (or 170 mg/dL) after
the glucose had been lowered into the target range, and deter-
mined which episodes of glucose excursion were associated with
potentially contributory protocol deviations.
Results. Fourteen women and 10 men were enrolled with a
mean age of 67  11 years. History of diabetes mellitus type 2 was
present in 21 (88%) subjects, and the remaining 3 were newly
diagnosed with it during hospitalization. The median admission
NIH Stroke Scale (NIHSS) score was 6 (range, 1 to 25).
In the 24 subjects the mean admission glucose was 14.7  4.9
mmol/L (or 264  88 mg/dL), and during insulin infusion it was
7.3  1.1 mmol/L (or 131  20 mg/dL). The mean glucose level
reached the target range 5 hours after starting insulin infusion.
Three peaks can be seen (figure) in the daily mean glucose level
during the 10th (10 to 11 AM), 14th (2 to 3 PM), and 19th (7 to 8 PM)
hours corresponding to three daily meals normally given to pa-
tients. Many subjects in this study resumed eating on the second
hospital day.
Table E-2 shows all the protocol deviations that contributed to
hypoglycemia and recurrent hyperglycemia (see table E-2 on the
Neurology Web site). At least one episode of hypoglycemia oc-
curred in 11 (46%) subjects, and protocol deviations accounted for
3 of 19 (16%) episodes. Symptomatic hypoglycemia occurred in five
(21%) subjects and included adrenergic manifestations in all five
and lethargy in one. All episodes of hypoglycemia were rapidly
detected, and all symptoms resolved completely within 30 minutes
after stopping insulin and giving concentrated glucose. The hypo-
glycemia episodes were not temporally related to neurologic dete-
riorations. Recurrent hyperglycemia occurred in 21 (88%) subjects,
and protocol deviations accounted for 9 of 48 (19%) episodes.
Seventeen (70.8%) subjects remained stable or improved con-
tinuously; four (16.7%) had neurologic deterioration (increase on
the NIHSS by 2 points) soon after admission and then improved;
and three (12.5%) with severe strokes (admission NIHSS, 18 to
25) died from stroke complications.
Discussion. Our insulin protocol, although still suboptimal,
represents a reasonable combination of simplicity, safety, and gly-
cemic control. Given the dynamic nature of cell death during acute
cerebral infarction, it is important to note that the glucose level
was lowered into the target range within 5 hours after starting
insulin.
Postprandial hyperglycemia appears to be a substantial con-
tributor to recurrent hyperglycemia. Individualized doses of rap-
idly acting subcutaneous insulin, given right after meals, should
reduce postprandial hyperglycemia within our protocol. Protocol
deviations can result in recurrent hyperglycemia and hypoglyce-
mia. The deviations will likely be minimized if the protocol is kept
simple and used frequently. Three revisions may further limit
hypoglycemia: 1) higher frequency of glucose monitoring or contin-
uous monitoring;6 2) including glucose in the insulin solution, as
was done in other studies;1,7 and 3) using a higher target range.
Good glycemic control during acute cerebral infarction in pa-
tients with diabetes mellitus type 2 is feasible and appears rela-
tively safe. We plan to make additional modifications to our
insulin protocol during a pilot clinical trial that is in progress. In
this pilot trial, we will evaluate the feasibility of randomized,
blinded treatment with IV (aggressive) vs subcutaneous (usual
care) insulin in patients with acute cerebral infarction and admis-
sion hyperglycemia.
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the April 27 issue to find the title link for this article.
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Figure. Mean glucose levels and insulin infusion rates in all
24 subjects during the entire treatment period synchronized
to one 24-hour period.   mean glucose; F  insulin rate.
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Sudden unilateral deafness due to a right
vertebral artery dissection
S.F.A. Raupp, MD; K. Jellema, MD; M. Sluzewski, MD, PhD;
P.L.M. de Kort, MD, PhD; and L.H. Visser, MD, PhD
Case report. We present a 42-year-old woman without a known
connective tissue disorder, who sought treatment at the emer-
gency department because of sudden right-sided deafness, vertigo,
and tendency to fall to the right. She also reported right-sided
neck pain for 3 days.
Neurologic examination, performed 1 day after the onset of
symptoms, revealed total deafness on the right side. There were
no other abnormalities, including no nystagmus (also not present
after use of Frenzel glasses) and no ataxia.
An MRI scan showed a small cerebellar infarction in the terri-
tory of the right posterior inferior cerebellar artery (PICA) on the
T2-weighted image (figure, A). On the sagittal T1-weighted im-
ages, the distal part of the right vertebral artery was hyperin-
tense, and no flow void was seen (not shown). A contrast-enhanced
MR angiography showed a normal proximal right vertebral artery
that showed irregularities and tapering in the high cervical por-
tion. The distal portion of the right vertebral artery was occluded
(figure, B and C).
The combination of image findings suggest vertebral
dissection.
In this patient, sudden deafness, vertigo, and neck pain were
caused by a spontaneous right vertebral artery dissection. The
patient was treated with low molecular weight heparin, especially
to prevent new neurologic signs and symptoms. During follow-up
evaluation, the unilateral deafness persisted without any other
sequelae.
The differential diagnosis of sudden deafness includes trauma,
viral disease, syphilis, Lyme disease, vascular disease, HIV, oto-
toxic drugs, autoimmune inner ear disease, perilymph fistulae,
Meniere disease, and acoustic neurinoma.1-3
The symptoms of sudden deafness combined with vertigo and
neck pain suggested the diagnosis of a vertebral artery dissection.
Discussion. Sudden deafness has been described in anterior
inferior cerebellar artery (AICA) infarction. Lee et al. described
the signs and symptoms of 12 patients with unilateral AICA in-
farction.1 Vertigo was the initial symptom in all patients, accom-
panied by a horizontal-rotatory nystagmus beating toward the
healthy side. Sensorineural hearing loss was present in 11 pa-
tients. Unlike our patient, all 12 patients had gait and limb ataxia
caused by involvement of the middle cerebellar peduncle or ante-
rior inferior cerebellum.1
Another recent article described bilateral deafness in vertebral
insufficiency caused by stenosis of the basilar artery. Vertigo was
present, but no nystagmus was observed in this patient as well.4
Our patient had unilateral sudden deafness caused by a right
vertebral dissection. In most patients, the internal auditory artery
originates from the AICA, but in a few, it branches off the PICA.
In our patient, most likely, small emboli originating from the
dissection caused a small selective cerebellar and cochlear infarc-
tion, sparing the vestibular apparatus. This led to unilateral sen-
sorineural hearing loss without nystagmus. In conclusion, for
patients presenting with neck pain and sudden unilateral sensori-
neural deafness, with or without vertigo, a vertebral artery dissec-
tion should be considered and MR angiography performed.
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Figure. (A) MRI (T2-weighted)
showing a small right-sided pos-
terior inferior cerebellar artery
(PICA) infarction. (B and C)
Contrast-enhanced MR angiog-
raphy showing a normal proxi-
mal right vertebral artery with
irregularities and tapering in
the high cervical portion.
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Plasmapheresis improves outcome in
postinfectious cerebellitis induced by
Epstein–Barr virus
Jeremy D. Schmahmann, MD
Postinfectious cerebellitis (PIC) is a rare complication of Epstein–
Barr virus (EBV) infection. Whereas its course is usually regarded
as self-limited, it can be prolonged and produce considerable resid-
ual disability. We report two adults with persistent PIC after EBV
infection who demonstrated complete and rapid recovery with a
course of plasmapheresis (total plasma exchange [TPE]).
Case reports. Case 1. A 20-year-old woman (Case 15 in ref-
erence 1) developed fever and myalgia, followed 2 weeks later by
onset over 3 days of slurred speech, gait instability, and difficulty
judging distances. Examination revealed hypermetric saccadic eye
movements, cerebellar dysarthria, dysmetria, dysdiadochokinesis,
and ataxic gait. She had flattened affect, decreased verbal output
and phonemic fluency, perseveration, and poor visual-spatial
planning. Results of strength, reflex, and sensory testing were
normal. Gadolinium-enhanced brain MRI and EEG were normal.
CSF revealed three lymphocytes, normal protein, and glucose.
Heterophile antibody was positive; serum EBV titer was 1:896;
EBV viral capsid was 1:1280; restricted immunoglobulin (Ig) G
was 1:320; and EBV nuclear antigen (EBNA) was 1:20, diagnostic
of chronic or recurrent EBV infection. CSF viral capsid, diffuse
and restricted IgG, and EBNA were normal. The persistence of
motor and cognitive symptoms at 1 month prompted treatment
with plasmapheresis. There was marked improvement in a step-
wise fashion the day after each of six sessions of TPE. One week
after treatment, the examination was only minimally abnormal,
and 1 month after treatment, all cerebellar motor tests and neu-
ropsychological tests had returned to normal, except for tests of
complex and unstructured list learning.
Case 2. A 28-year-old man developed fever, myalgia, and
pharyngitis. Two to 3 weeks later he had vertigo, ataxia, dysar-
thria, untidy handwriting, and incoordination of his limbs. He had
difficulty concentrating and making quick decisions, and his fam-
ily noted a flattened affect. Brain MRI and EEG were normal.
EBV IgG titer was 1:640; IgM was elevated (1/10); and EBNA was
negative, consistent with primary infection 6 weeks previously.
Symptoms persisted, and examination 3 months after the onset of
the illness revealed hypermetric saccades, cerebellar dysarthria,
upper extremity rebound, dysmetria and dysdiadochokinesis, wid-
ened stance, and ataxic gait. Strength, reflexes, and sensation
were normal. Attention, declarative learning, and phonemic flu-
ency were reduced; thinking was concrete; and he perseverated on
the Luria diagram. This lack of recovery prompted treatment with
plasmapheresis. During the course of five TPE sessions, the cere-
bellar motor syndrome abruptly improved, and thinking and per-
sonality reverted to the premorbid state. Three months after TPE,
the examination was normal.
Discussion. Acute cerebellar meningoencephalitis from EBV
infection is rare, occurring more commonly in children than in
adults. It is characterized by an acute pancerebellar syndrome
sometimes with brainstem signs or diffuse encephalitis, meningis-
mus, CSF pleocytosis, positive serologic tests for EBV in the CSF,
and MRI abnormalities.
In contrast, PIC is thought to be an immune-mediated re-
sponse to viral infection occurring 1 to 3 weeks later (range, 1 to
43 days2), characterized by ataxia and dysmetria2 with minimal
CSF leukocytosis, no systemic features, and negative CSF EBV
titers despite positive serum titers. Neuropsychiatric features are
also observed.1,2 MRI is usually normal, but SPECT scans may
show decreased3 or increased perfusion.4
Reports generally stress the benign nature of postinfectious
cerebellar ataxia,5 but Connolly et al.2 found that residual motor
and cognitive deficits persisted for months or years, and in some
cases deficits were permanent. Persistent cerebellar ataxia has
also been noted in adults.6
Both our patients remained prominently compromised 1 month
and 3 months after the onset of symptoms, and this time course,
together with serologic tests in both patients and CSF analysis in
Case 1, supported the diagnosis of EBV PIC. Continued clinical
disability prompted the decision to treat. Recovery was rapid,
complete, and occurred within days of the full course of conven-
tional TPE (five to six exchanges), indicating a cause-and-effect
relationship.
Successful improvement of PIC with IV Ig has been noted, but
to our knowledge there are no published accounts of the use of
TPE in this disorder.4,7 The success of TPE in our patients sug-
gests that immune-modulating therapy may limit the duration of
illness and potential long-term motor and cognitive deficits in
patients with PIC from EBV. Prospective clinical trials could ad-
dress this possibility more rigorously. The rapid recovery of PIC
with TPE 3 months into the illness also implies that there is a
protracted stage of antibody-mediated, reversible neuronal toxic-
ity before Purkinje cell death.
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Insulinoma misdiagnosed as intractable
epilepsy
M.-H. Dion, MD; P. Cossette, MD, MSc; J.-M. St-Hilaire, MD;
E. Rasio, MD; and D.K. Nguyen, MD
Many conditions may mimic epileptic seizures, including move-
ment disorders, cardiac arrhythmias, psychiatric disorders, or
metabolic anomalies. Among these, insulinoma is a rare but cur-
able cause of hypoglycemia often misdiagnosed as epilepsy or a
psychiatric disorder. We report three patients with hypoglycemic
spells caused by insulinoma. All patients were diagnosed during a
video-EEG monitoring session initially performed for the evalua-
tion of intractable epilepsy.
Case reports. Case 1. A 37-year-old woman had a 6-year
history of stereotyped paroxysmal episodes of paresthesias of the
left arm, spreading to the face and lower limbs, and lasting ~20
minutes. Episodes could last up to 2 hours and included gait
incoordination, mild agitation, emotional lability, and incoherent
speech, which was followed by fatigue. Frequency of the attacks
gradually increased up to twice a week. The patient was initially
diagnosed with partial epilepsy, refractory to carbamazepine. No
interictal activity was recorded during a prolonged video-EEG
monitoring. Brain MRI was normal, and interictal SPECT re-
vealed bifrontal and right posterior temporal hypoperfusion. A
fasting blood glucose level was obtained and showed mild hypogly-
cemia at 3.2 mmol/L (normal, 3.8 to 6.1 mmol/L). A prolonged fast
reproduced a typical attack after 8 hours, along with concomitant
severe hypoglycemia (0.9 mmol/L) and high insulin levels, con-
firming the diagnosis of insulinoma. An endoscopic ultrasound
detected a small 1.5-cm nodular lesion over the pancreatic tail.
Surgical removal of the tumor led to full remission of the
symptoms.
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Case 2. A 44-year-old man had a 2-week history of spells
characterized by awkward behavior (crawling, swimming, circling,
slamming, and vocalizations), unresponsiveness, and paranoia.
Most of these episodes occurred late at night or early morning,
lasting from 30 minutes to 6 hours, followed by sleepiness. The
attacks increased in intensity and frequency up to a daily basis.
These spells were initially misdiagnosed as anxiety disorder and
then as complex partial seizures refractory to valproic acid. The
EEG, head CT, and glucose levels were normal. A prolonged fast
was performed during concomitant video-EEG monitoring. A typi-
cal attack was induced after 5 hours associated with ictal diffuse
slow waves and significant low blood glucose level (1.7 mmol/L).
Concomitant insulin and C-peptide measures confirmed the inap-
propriate secretion of insulin. An abdominal CT revealed a 2-cm
mass. The patient was cured by a distal pancreatectomy.
Case 3. A 55-year-old woman had a 7-month history of epi-
sodic stereotyped confusional spells characterized by psychomotor
slowing, unresponsiveness, abnormal posturing, and perseverative
unpurposeful behavior. The attacks lasted from a few minutes to 6
hours and occurred up to three times a day despite treatment with
carbamazepine and clobazam. Routine serum glucose levels and
brain MRI were normal. The patient was admitted to our epilepsy
unit with a working diagnosis of psychogenic nonepileptic sei-
zures. No epileptic interictal activity was observed during pro-
longed video-EEG monitoring. A typical attack was recorded,
associated with diffuse slow waves (figure, A), during spontaneous
hypoglycemia (1.4 mmol/L). A prolonged fast was performed and
induced a spell after 9 hours with simultaneous low blood glucose
(1.3 mmol/L) and high insulin and C-peptide levels. Abdominal
MRI demonstrated a 1-cm lesion in the pancreatic tail (figure, B).
The patient was cured by resection of the lesion.
Discussion. Insulinomas may lead to fasting hypoglycemic
spells caused by excessive (and time-inappropriate) secretion of
insulin. Insulinomas are rare, with 4 cases per 1 million patients
each year.1 The majority (90%) are benign solitary adenomas,
whereas up to 10% are associated with multiple endocrine neopla-
sia type I syndromes.1 The main challenge of these rare tumors is
their recognition.2,3 Patients are frequently misdiagnosed with ep-
ilepsy or a psychiatric disorder, which was the case in our three
patients. It is possible that some of the spells were complex partial
seizures secondary to hypoglycemia, although this is doubtful be-
cause spells were atypical in semiology, lengthy in duration, unre-
sponsive to anticonvulsant agents, and not associated with ictal
epileptic activity during monitoring. In a recent series, median
interval from onset of symptoms to diagnosis is 2 years, with a
range of 1 month to 30 years.2 The diagnostic delay in our patients
ranged from 6 months to 8 years. Fortunately, none experienced
serious consequences. Late recognition may be caused by many
factors, including the rarity of the condition, the lack of specificity
of most symptoms, and the blunt of autonomic symptoms from
Figure. (A) Mixture of diffuse moder-
ate to high amplitude theta and delta
semirhythmic activity during an epi-
sode (filters used: high-frequency filter,
35 Hz; low-frequency filter, 1 Hz). (B)
Abdominal MRI showing a nodular
pancreatic lesion.
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deficient counter-regulatory hyperadrenergic responses.4 The
presence of atypical behavioral spells that are prolonged, recur-
rent, unresponsive to anticonvulsant agents, and occurring typi-
cally after prolonged fast should raise the possibility of
hypoglycemia secondary to insulinoma.
The finding of low glucose level in a patient who appears
healthy with no coexisting disease warrants further investigation.
However, as exhibited in these three patients, a normal result
does not exclude the presence of hypoglycemia. When clinically
suspected, a supervised prolonged fast (up to 72 hours) under
close monitoring should be performed to assess the role of inappro-
priate secretion of insulin in the genesis of hypoglycemia. A glu-
cose level 45 mg/dL (2.5 mmol/L), a C-peptide level 0.2 nmol/L,
and an insulin level 6 mU/mL (36 pmol/L) confirms the diagno-
sis of insulinoma.5 Localization of tumor could then be assessed by
various studies, including abdominal ultrasound, abdominal CT or
MRI, selective arteriogram, endoscopic ultrasound, and intraoper-
ative ultrasound.6
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Changes in the appearance of venous sinuses
after treatment of disordered intracranial
pressure
Devra B. Baryshnik, MD; and Richard I. Farb, MD
Cerebral angiographic findings in idiopathic intracranial hyper-
tension (IIH) and spontaneous intracranial hypotension (SIH)
have been described. Conventional cerebral venography has dem-
onstrated tapered stenoses and filling defects in the transverse
sinuses of patients with IIH.1 These stenoses have also been found
in 90% of IIH patients imaged with auto-triggered elliptic-
centric-ordered three-dimensional gadolinium-enhanced MR
venography (ATECO MRV).2 Conventional cerebral angiography
demonstrated prominence of intracranial venous structures in pa-
tients with SIH.3 To date, MRI correlates of these dilated venous
channels have not been described. This report discusses the use of
ATECO MRV to demonstrate the normalization of venous sinus
caliber associated with the resolution of these two disorders of
intracranial pressure (ICP).
Case reports. Case 1. A 21-year-old woman was diagnosed
with IIH. CSF opening pressure was 32.5 cm H2O. Months later,
she was admitted to our institution with persistent headache and
blurred vision despite maximal doses of acetazolamide. Examina-
tion revealed an obese woman with bilateral papilledema. CSF
opening pressure remained elevated at 24 cm H2O. An MRI of the
brain was normal. An ATECO MRV demonstrated the typical
stenotic appearance of the dural sinuses (figure, A).2 A ventriculo-
peritoneal shunt was inserted, resulting in symptom resolution.
Eighteen months later, the patient had refractory headaches
exacerbated by activity, photophobia, nausea, and vomiting. Her
medications included acetazolamide 250 mg twice daily and acet-
aminophen 300 mg/codeine 30 mg two to nine tablets daily for 3
months. CSF pressure was normal (19 cm H2O). A CSF nuclear
medicine flow study was normal. MRI of the brain demonstrated
dural enhancement secondary to the shunt. ATECO MRV re-
vealed normal-appearing venous sinuses with resolution of dural
sinus narrowing (figure, B). The patient was diagnosed with
transformed migraine secondary to medication overuse.
Case 2. A previously healthy 19-year-old woman with head-
ache and diplopia was transferred to our institution. Her head-
ache was sudden in onset, exacerbated by movement, and severe
in the upright position. Examination revealed bilateral abducens
palsies. MRI revealed findings typical of intracranial hypotension,
Figure. Paired right anterior oblique
and left anterior oblique auto-triggered
elliptic-centric-ordered three-
dimensional gadolinium-enhanced MR
(ATECO MR) venogram maximum in-
tensity projection (MIP) images. (A) Pa-
tient with idiopathic intracranial
hypertension (IIH) before shunt proce-
dure; CSF opening pressure  24 cm
H2O. (B) Same patient after shunt pro-
cedure; CSF opening pressure  19 cm
H2O. (C) Patient with spontaneous in-
tracranial hypotension (SIH) before
blood patch procedure. (D) Same pa-
tient after blood patch procedure and
resolution of symptoms. Open arrows
(A and C) denote abnormal venous si-
nus caliber before treatment; closed ar-
rows (B and D) denote normalization of
venous sinus caliber post-treatment.
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including inferior displacement of the cerebellar tonsils, flattening
of the anterior aspect of the pons, small bilateral subdural hygro-
mas, thickened appearance of the dura, and diffuse pachymenin-
geal enhancement after gadolinium injection.4 An ATECO MRV
demonstrated dilatation of the dural venous sinuses (figure, C). A
diagnosis of SIH was made. She was treated with a blood patch,
and the headache improved. One year later, repeat imaging re-
vealed resolution of the aforementioned stigmata of intracranial
hypotension. Specifically, the dural venous sinuses returned to
normal caliber (figure, D).
Discussion. These cases demonstrate normalization of venous
sinus caliber associated with the resolution of IIH and SIH. The
improved imaging and noninvasive nature of ATECO MRV over
other venographic techniques have made this possible.5 The dy-
namic changes in venous sinus caliber can be explained using the
Monro–Kellie hypothesis.6 In IIH, the increase in CSF pressure is
compensated for by a decrease in the intracranial blood volume.
We propose that the dural venous sinuses act as a volume-
pressure reservoir that can accommodate these changes. This is
seen on ATECO MRV by apparent venous sinus stenosis in pa-
tients with IIH. Using the same reasoning, in SIH, a decrease in
CSF volume (and thus decrease in pressure) would be accompa-
nied by an increase in the intracranial blood volume. This is seen
on ATECO MRV as enlargement of the dural venous sinuses.
Although CSF leakage into extradural space has been accepted
as the etiology of SIH, the pathophysiology of IIH has yet to be
fully delineated. Cerebral venous manometry in patients with IIH
demonstrated a pressure gradient along the transverse sinuses,
suggesting the presence of a functional obstruction to venous out-
flow.1 Subsequent investigations demonstrated that removal of 20
to 25 mL of CSF corresponded with decrease in central venous
sinus pressure, suggesting that the obstruction to venous outflow
in IIH is a secondary phenomenon.7 These researchers were un-
able to use venography to demonstrate the normalization of the
appearance of the dural venous sinuses with improvement of CSF
pressure.
Case 1 provides evidence that the narrowing in the transverse
sinuses seen with elevated ICP is reversible when ICP normalizes.
This supports the hypothesis that the deformity of the venous
sinuses in IIH is a secondary event. Case 2 demonstrates the
complementary phenomenon of normalization of venous sinus cal-
iber after clinical and imaging resolution of SIH.
These findings suggest that there is a direct and dynamic
relationship between CSF pressure and the appearance of the
venous sinuses.
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Auditory dysfunction in chronic inflammatory
demyelinating polyradiculoneuropathy
Gerald J.D. Hengstman, MD; Helenius J. Schelhaas, MD; and
Machiel J. Zwarts, MD, PhD
Cranial nerve involvement, most commonly affecting the facial
and oculomotor nerves, has been reported in chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP).1,2 Symptomatic in-
volvement of the vestibulocochlear nerve has been described at
least once but only in the vestibular part of the nerve.1
We describe a patient who presented with a relapse of CIDP
accompanied by sudden bilateral sensorineural hearing loss.
Brainstem auditory evoked potentials (BAEPs) confirmed bilat-
eral retrocochlear dysfunction. Treatment with high-dose pred-
nisone was associated with nearly complete recovery clinically and
neurophysiologically.
Case report. A 66-year-old man sought treatment for sudden
bilateral hearing loss and paraesthesias of the lower extremities.
Ten months earlier, CIDP had been diagnosed based on clinical
signs and symptoms (symmetric muscle weakness, sensory ataxia,
distal hypesthesia, and absent tendon reflexes), results of nerve
conduction studies (i.e., motor distal latency and F waves of the
ulnar and median nerves 130% of the upper limit of normal,
slowing of nerve conduction velocities in ulnar and peroneal
nerves 70% of the lower limit of normal, and presence of a
conduction block in the peroneal nerve), and CSF analysis (ele-
vated protein without pleocytosis).3 He was treated with IV gam-
maglobulin, which had resulted in a nearly full recovery. At
presentation, he did not use any medications besides the occa-
sional use of ciprofloxacin for recurrent cystitis and vitamin B12
supplementation once a month.
At presentation, the patient had sudden bilateral hearing loss
and hypesthesia of the feet. He had not noted a change in muscle
strength or vertigo. Physical examination showed no abnormali-
ties of the cranial nerves, with the exception of bilateral sensori-
neural hearing loss. There was areflexia and hypesthesia in the
feet. Muscle strength was normal with the exception of slight
weakness of the anterior tibial muscles. There was no ataxia.
Otoscopy and measurement of pure-tone air and bone conduction
thresholds were normal. A pure-tone audiogram revealed a 50-dB
HL sensorineural and a 20-dB HL conductive hearing loss on both
sides. No BAEP could be elicited at 80 and 90 dB hearing level
(HL) for both ears. At 105 dB HL, a BAEP was recorded that
showed cochlear microphonic potentials, no reproducible peak I
and III, delayed peak II, delayed peak IV, and a delayed peak V on
the right side and cochlear microphonic potentials, no reproduc-
ible peak I and IV, delayed peak II, delayed peak III, and a
delayed peak V on the left side (figure, A). The interpeak latency
between III and V was slightly increased. Vestibular function
tests, including horizontal saccades, smooth pursuit, optokinetic
nystagmus, and quantitative rotational testing of the vestibulo-
ocular reflexes, were normal.
The absence of a reproducible peak I on both sides, the in-
creased absolute latencies of all recordable peaks on both sides
(even after correction for hearing loss), and the presence of co-
chlear microphonic potentials suggested a disorder of the cochlear
nerve. Because the patient had clinical signs and symptoms sug-
gestive of a relapse of the CIDP, the retrocochlear hearing loss
was interpreted as a result of a relapse of the inflammatory demy-
elinating disorder. Treatment with oral prednisone (50 mg once a
day) was started. Nearly all symptoms resolved within 1 month,
and a second pure-tone audiogram demonstrated a residual senso-
rineural hearing loss of 20 dB HL on the left side and 30 dB HL on
the right side. A second BAEP study showed normal responses on
both sides with normal interpeak latencies (figure, B).
Discussion. Cranial nerve involvement is well documented in
CIDP and most commonly affects the facial and oculomotor
nerves.1,2 At least one patient with CIDP and symptomatic in-
volvement of the vestibulocochlear nerve has been described, but
only the vestibular part of the eighth cranial nerve was involved.1
Our patient is, as far as we know, the first patient described with
CIDP and symptomatic involvement of the cochlear part of the
vestibulocochlear nerve.
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Abnormal BAEPs in patients with CIDP have been described,
but none of these patients had auditory symptoms.4-6 Moreover, in
these studies a second BAEP investigation was not performed
after management of the CIDP, thus leaving unanswered the
question whether BAEP abnormalities are reversible, as might be
expected in an immune-mediated demyelinating disorder. The re-
sults of the second BAEP study in our patient clearly showed that
the BAEP abnormalities were reversible.
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Figure. Brainstem auditory evoked potentials (BAEPs) recorded from A1-Cz and A2-Cz before and after treatment with
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